What is the current Maternal Blood Test market size?

The current Maternal Blood Test market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Maternal Blood Test market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Maternal Blood Test market?

Key drivers include rising prenatal testing, technological advancements, and growing awareness of non-invasive tests.

What are the major challenges facing the Maternal Blood Test market?

Challenges include high test costs, regulatory hurdles, and limited accessibility in developing regions.

Which regions are leading the Maternal Blood Test market?

North America and Europe are currently leading the market due to high adoption rates and advanced healthcare infrastructure.

Who are the top companies in the Maternal Blood Test market?

Top companies include Illumina, Roche, and Quest Diagnostics, which offer a range of prenatal testing products.

What future opportunities exist in the Maternal Blood Test market?

Future opportunities include expanding into emerging markets and developing new non-invasive tests for various pregnancy-related conditions.

How is technology impacting the Maternal Blood Test market?

Technology is driving growth through advancements in genomics, artificial intelligence, and digital health, enabling more accurate and efficient testing.

What is the current regulatory landscape for the Maternal Blood Test market?

The regulatory landscape is evolving, with increasing focus on test validation, reimbursement, and patient data protection.

What is the future outlook for the Maternal Blood Test market?

The future outlook is positive, with growing demand for non-invasive prenatal testing driving market growth and innovation.

Maternal Blood Test Growth, Trends & Forecast Outlook 2033

Maternal Blood Test by Application (Edwards Syndrome, Patau Syndrome, Down syndrome, Neural Tube Defects, Other), by Types (Combined First Trimester Screening, Second Trimester Maternal Serum Screening), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $4126 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $4126 million

CAGR: 8.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Maternal Blood Test Market Overview

The Maternal Blood Test market refers to the industry that provides non-invasive prenatal tests to detect genetic disorders and chromosomal abnormalities in fetuses. As a crucial aspect of prenatal care, the Maternal Blood Test market size is estimated to be around $1.4 billion. The growth outlook for this market is promising, with a market forecast that indicates significant expansion over the next few years. The industry expansion is driven by factors such as increasing demand for non-invasive prenatal testing, advancements in technology, and rising awareness about genetic disorders. The primary keywords in this market include Maternal Blood Test market size, growth outlook, market forecast, and industry expansion.

Loading chart…

The Maternal Blood Test market is expected to grow at a CAGR of 10.5% from 2026 to 2033, driven by macro drivers such as technological advancements, changing consumer behavior, and increasing competition. Key forces shaping the industry include technology shifts towards non-invasive prenatal testing, regulatory approvals for new tests, and consumer awareness about genetic disorders. The largest region for the Maternal Blood Test market is North America, while the fastest-growing region is Asia-Pacific. The market growth is expected to be driven by increasing demand for non-invasive prenatal testing and rising awareness about genetic disorders.

Report Overview

Report Attribute	Details
Market size value in 2025	4.13 billion
Revenue forecast in 2033	7.20 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CENTOGENE NV; SEQUENOM; Natera, Inc.; LifeLabs Genetics; Sema4 OpCo, Inc.; Invitae Corporation; Illumina, Inc.; Thermo Fisher Scientific Inc.; General Electric; PerkinElmer Inc.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; YOURGENE HEALTH; Eurofins Scientific; EKF Diagnostics; BGI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Maternal Blood Test market is poised for significant growth, driven by various factors. The market dynamics are shaped by a combination of growth drivers, restraints, opportunities, and challenges.

Growth Drivers2 items

Advances in non-invasive prenatal testing technologies are expanding the Maternal Blood Test market size, enabling early detection of genetic disorders and chromosomal abnormalities, which is driving demand for these tests.

Increasing awareness about the importance of prenatal testing and diagnosis among expecting mothers is contributing to the growth forecast of the Maternal Blood Test market, particularly in developed economies.

Restraints2 items

High costs associated with Maternal Blood Test procedures are limiting their adoption in low- and middle-income countries, where healthcare infrastructure and reimbursement policies are not well-established.

Stringent regulatory frameworks governing the approval and commercialization of Maternal Blood Test products are hindering the entry of new players into the market, thereby restricting competition and innovation.

Opportunities2 items

The rising demand for personalized medicine and targeted therapies is creating opportunities for companies to develop and market specialized Maternal Blood Test products, catering to specific patient needs and preferences.

Emerging economies, such as China and India, offer significant growth opportunities for the Maternal Blood Test market, driven by increasing healthcare spending, improving infrastructure, and a growing middle-class population.

Challenges2 items

Ensuring the accuracy and reliability of Maternal Blood Test results is a major challenge, as false positives or false negatives can have serious consequences for patients and their families.

The Maternal Blood Test market is highly competitive, with several established players and new entrants vying for market share, which can lead to pricing pressures and margin erosion for companies operating in this space.

Market Segmentation

Loading chart…

The Application segment of the Maternal Blood Test market refers to the various uses of these tests in prenatal care. This segment is crucial in understanding the Maternal Blood Test segmentation and its impact on the overall market size. The application of Maternal Blood Tests includes screening for genetic disorders, fetal infections, and other pregnancy-related complications. This segment contributes significantly to the market size, as it encompasses a wide range of tests and services that cater to the diverse needs of expectant mothers.

The Types segment of the Maternal Blood Test market is further divided into subtypes, including non-invasive prenatal testing (NIPT) and invasive prenatal testing. NIPT includes tests such as cell-free DNA testing, which analyzes the fetal DNA present in the mother's blood to detect genetic abnormalities. Invasive prenatal testing, on the other hand, involves procedures like amniocentesis and chorionic villus sampling (CVS) to collect fetal cells for analysis. Understanding the market taxonomy of these subtypes is essential to determine their contribution to the overall market size and growth.

Maternal Blood Test Segmentation Breakdown9 items

Application

Edwards Syndrome

Patau Syndrome

Down syndrome

Neural Tube Defects

Other

Types

Combined First Trimester Screening

Second Trimester Maternal Serum Screening

Regional Insights

Loading chart…

The Maternal Blood Test market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of non-invasive prenatal testing and rising investments in healthcare infrastructure.

Key drivers for each region include: for North America, policies supporting prenatal care and demographics with a high birth rate; for Europe, ecosystem maturity and adoption of advanced diagnostic technologies; for Asia Pacific, infrastructure development and investments in research and development; for Latin America, demographics with a growing young population and policies focused on maternal health; and for Middle East & Africa, infrastructure expansion and adoption of innovative diagnostic solutions.

The regional forecast indicates that the Maternal Blood Test market will experience significant growth, driven by increasing demand for non-invasive prenatal testing and rising awareness of maternal health. As the market continues to evolve, it is essential to monitor regional trends and market dynamics to capitalize on emerging opportunities and stay competitive.

Competitive Landscape

The Maternal Blood Test market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. Understanding the Maternal Blood Test competitive landscape is crucial for navigating this complex market, where companies must balance innovation with cost control.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on technology, service model, channel strength, customization, and cost advantages. The following companies are notable for their strategic focus:

CENTOGENE NV: Regional expansion

Natera, Inc.: Innovation pipeline

LifeLabs Genetics: Local manufacturing

Sema4 OpCo, Inc.: Premium pricing

Invitae Corporation: Vertical integration

Illumina, Inc.: OEM tie-ups

Key Maternal Blood Test Companies16 items

CENTOGENE NV

SEQUENOM

Natera, Inc.

LifeLabs Genetics

Sema4 OpCo, Inc.

Invitae Corporation

Illumina, Inc.

Thermo Fisher Scientific Inc.

General Electric

PerkinElmer Inc.

Agilent Technologies, Inc.

F. Hoffmann-La Roche Ltd

YOURGENE HEALTH

Eurofins Scientific

EKF Diagnostics

BGI

Market Ecosystem

The Maternal Blood Test ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. Value is created and captured through the development, integration, and delivery of maternal blood testing products and services. This ecosystem can be broadly segmented into three main stages: upstream, midstream, and downstream, with each stage involving distinct roles and interactions.

Raw material/component suppliers — provide reagents and equipment

Technology providers — develop testing platforms and software

OEMs / manufacturers — produce testing kits and devices

System integrators / EPCs — integrate testing systems and infrastructure

Distributors / channel partners — supply products to healthcare providers

Service providers / after-sales — offer maintenance and support services

End users / buyers — utilize maternal blood testing products and services

In the Maternal Blood Test ecosystem, value flows through the interactions and relationships among these participants. Control points, such as regulatory approvals and standards, influence the adoption of maternal blood testing products and services. Dependency risks, including input constraints and approval timelines, can impact the ecosystem's efficiency. As part of a broader value chain analysis, understanding these dynamics is crucial for navigating the Maternal Blood Test ecosystem, where switching costs, partnerships, and interoperability requirements can vary by region and market segment.

Recent Industry Insights

The Maternal Blood Test industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Illumina and Roche, have focused on advancing non-invasive prenatal testing. Mergers and acquisitions, like the acquisition of Ariosa Diagnostics by Roche, have also played a crucial role in shaping the industry. Furthermore, product launches, such as the introduction of new next-generation sequencing technologies, have improved the accuracy and reliability of maternal blood tests.

Additionally, regulatory changes and funding rounds have supported the growth of the Maternal Blood Test industry. The shift in consumer trends towards personalized medicine and increased awareness about prenatal testing has also driven the demand for maternal blood tests. As a result, companies are expanding their product portfolios and investing in research and development to stay ahead in the market, ultimately driving the Maternal Blood Test industry trends forward.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Maternal Blood Test market outlook is that it presents a highly attractive opportunity for growth, driven by increasing demand for non-invasive prenatal testing and advancements in technology. The competitive intensity is moderate, with key players focusing on innovation and expansion into new markets.

The long-term outlook for the Maternal Blood Test market is positive, with innovation in areas such as cell-free DNA testing and machine learning expected to drive growth. However, the demand–supply balance may be affected by key risk factors, including regulatory changes and reimbursement issues. Overall, the market is poised for significant expansion, with opportunities for new entrants and established players alike to capitalize on the growing demand for maternal blood tests.

11 items

1. Executive Summary

2. Maternal Blood Test Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Maternal Blood Test Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Maternal Blood Test Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Edwards Syndrome

6.1.2. Patau Syndrome

6.1.3. Down syndrome

6.1.4. Neural Tube Defects

6.1.5. Other

6.2. Global Maternal Blood Test Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Combined First Trimester Screening

6.2.2. Second Trimester Maternal Serum Screening

6.3. Global Maternal Blood Test Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Maternal Blood Test Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Maternal Blood Test Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Maternal Blood Test Market Competition by Key Manufacturers

8.1. Global Maternal Blood Test Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Maternal Blood Test: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. CENTOGENE NV

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. SEQUENOM

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Natera, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. LifeLabs Genetics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sema4 OpCo, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Invitae Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Thermo Fisher Scientific Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. General Electric

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. PerkinElmer Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Agilent Technologies, Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. F. Hoffmann-La Roche Ltd

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. YOURGENE HEALTH

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Eurofins Scientific

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. EKF Diagnostics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. BGI

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Maternal Blood Test Market

Figure 4: Global Maternal Blood Test Market: Drivers

Figure 5: Global Maternal Blood Test Market: Challenges

Figure 6: Global Maternal Blood Test Market: Trends

Figure 7: Global Maternal Blood Test Market: Opportunity

Figure 8: Global Maternal Blood Test Market: Restraint

Figure 9: Global Maternal Blood Test Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Maternal Blood Test Market Value (USD Million) By Region

Figure 15: Global Maternal Blood Test Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Maternal Blood Test Market Value (USD Million) By Region

Figure 23: Global Maternal Blood Test Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Maternal Blood Test Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Maternal Blood Test Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Maternal Blood Test Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Maternal Blood Test Market Value (USD Million) By Region

Table 10: Global Maternal Blood Test Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Maternal Blood Test Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Maternal Blood Test Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Maternal Blood Test Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: CENTOGENE NV Basic Information And Sales Area

Table 31: CENTOGENE NV. Products Portfolio

Table 32: SEQUENOM Basic Information And Sales Area

Table 33: SEQUENOM. Products Portfolio

Table 34: Natera, Inc. Basic Information And Sales Area

Table 35: Natera, Inc.. Products Portfolio

Table 36: LifeLabs Genetics Basic Information And Sales Area

Table 37: LifeLabs Genetics. Products Portfolio

Table 38: Sema4 OpCo, Inc. Basic Information And Sales Area

Table 39: Sema4 OpCo, Inc.. Products Portfolio

Table 40: Invitae Corporation Basic Information And Sales Area

Table 41: Invitae Corporation. Products Portfolio

Table 42: Illumina, Inc. Basic Information And Sales Area

Table 43: Illumina, Inc.. Products Portfolio

Table 44: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 45: Thermo Fisher Scientific Inc.. Products Portfolio

Table 46: General Electric Basic Information And Sales Area

Table 47: General Electric. Products Portfolio

Table 48: PerkinElmer Inc. Basic Information And Sales Area

Table 49: PerkinElmer Inc.. Products Portfolio

Table 50: Agilent Technologies, Inc. Basic Information And Sales Area

Table 51: Agilent Technologies, Inc.. Products Portfolio

Table 52: F. Hoffmann-La Roche Ltd Basic Information And Sales Area

Table 53: F. Hoffmann-La Roche Ltd. Products Portfolio

Table 54: YOURGENE HEALTH Basic Information And Sales Area

Table 55: YOURGENE HEALTH. Products Portfolio

Table 56: Eurofins Scientific Basic Information And Sales Area

Table 57: Eurofins Scientific. Products Portfolio

Table 58: EKF Diagnostics Basic Information And Sales Area

Table 59: EKF Diagnostics. Products Portfolio

Table 60: BGI Basic Information And Sales Area

Table 61: BGI. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Maternal Blood Test Market Value (USD Million) By Region

Table 67: Global Maternal Blood Test Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Maternal Blood Test Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.13 billion
Revenue forecast in 2033	7.20 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CENTOGENE NV; SEQUENOM; Natera, Inc.; LifeLabs Genetics; Sema4 OpCo, Inc.; Invitae Corporation; Illumina, Inc.; Thermo Fisher Scientific Inc.; General Electric; PerkinElmer Inc.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; YOURGENE HEALTH; Eurofins Scientific; EKF Diagnostics; BGI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Ensuring the accuracy and reliability of Maternal Blood Test results is a major challenge, as false positives or false negatives can have serious consequences for patients and their families.

Market Segmentation

Loading chart…

Maternal Blood Test Segmentation Breakdown9 items

Application

Edwards Syndrome

Patau Syndrome

Down syndrome

Neural Tube Defects

Other

Types

Combined First Trimester Screening

Second Trimester Maternal Serum Screening

Regional Insights

Loading chart…

Competitive Landscape

CENTOGENE NV: Regional expansion

Natera, Inc.: Innovation pipeline

LifeLabs Genetics: Local manufacturing

Sema4 OpCo, Inc.: Premium pricing

Invitae Corporation: Vertical integration

Illumina, Inc.: OEM tie-ups

Key Maternal Blood Test Companies16 items

CENTOGENE NV

SEQUENOM

Natera, Inc.

LifeLabs Genetics

Sema4 OpCo, Inc.

Invitae Corporation

Illumina, Inc.

Thermo Fisher Scientific Inc.

General Electric

PerkinElmer Inc.

Agilent Technologies, Inc.

F. Hoffmann-La Roche Ltd

YOURGENE HEALTH

Eurofins Scientific

EKF Diagnostics

BGI

Market Ecosystem

Raw material/component suppliers — provide reagents and equipment

Technology providers — develop testing platforms and software

OEMs / manufacturers — produce testing kits and devices

System integrators / EPCs — integrate testing systems and infrastructure

Distributors / channel partners — supply products to healthcare providers

Service providers / after-sales — offer maintenance and support services

End users / buyers — utilize maternal blood testing products and services

Recent Industry Insights

Analyst Overview

Table of Contents